...
首页> 外文期刊>Journal of Clinical and Diagnostic Research >Study of Changes in Renal Function by Perindopril and Telmisartan during Treatment of Systemic Hypertension
【24h】

Study of Changes in Renal Function by Perindopril and Telmisartan during Treatment of Systemic Hypertension

机译:培哚普利和替米沙坦治疗系统性高血压期间肾功能变化的研究

获取原文

摘要

Background: Angiotensin Converting Enzyme Inhibitors (ACEI) and Angiotensin Receptor Blockers (ARBs) has been a major therapeutic advance in the management of hypertensive patients. This study was designed to compare adverse effects on renal markers in treatment with two commonly used drugs Perindopril and Telmisartan in cases of Hypertension. This was an ?observational? and ?cross-sectional? study. Methods: This study was conducted in two groups, Group A (Newly diagnosed hypertensive patients) and Group B (Old but poorly controlled hypertensive), each had 100 patients. In both groups, half the patients were given Perindopril 4 mg OD and half were given Telmisartan 40 mg OD for 24 weeks. If blood pressure was not controlled, dose was titrated to response and increased to 8 mg OD and 80 mg OD for Perindopril and Telmisartan respectively to keep mean arterial pressure between 90?115 mmHg. The adjusted dose was kept constant in both groups. Blood urea, serum creatinine and creatinine clearance was estimated initially and then at 4th, 12th and 24th week. Results: Treatment with Perindopril showed that mean baseline values for blood urea, serum creatinine and creatinine clearance in newly diagnosed and old hypertensive patients were 30.88, 1.37, 64.09 and 33.68, 1.53, 55.98, respectively. After study period these values were 32.24, 1.40, 63.97 and 29.80, 1.46, 59.23 respectively (p value > 0.05). Treatment with telmisartan showed that mean baseline values of blood urea, serum creatinine and creatinine clearance in both group of patients were 30.88, 1.52, 59.31, and 31.72, 1.40, 65.67, respectively. After treatment these values in both groups were 31.92, 1.43, 62.66; and 32.20, 1.46, 61.70, respectively (p value > 0.05). Conclusion: It concluded that both Perindopril and Telmisartan significantly reduces systolic, diastolic and mean arterial pressure without any significant effect on renal function in both newly diagnosed and old hypertensive patients.
机译:背景:血管紧张素转换酶抑制剂(ACEI)和血管紧张素受体阻滞剂(ARBs)已成为高血压患者治疗的主要治疗进展。本研究旨在比较高血压患者使用两种常用药物培哚普利和替米沙坦治疗对肾标志物的不良影响。这是一个“观察性”吗?和“横截面”?研究。方法:本研究分为两组,即A组(新诊断的高血压患者)和B组(旧但控制不良的高血压),每组100例患者。两组患者中,有24周的患者半数接受培哚普利4 OD OD,一半接受替米沙坦40 mg OD。如果血压不受控制,则将剂量调整为响应剂量,培哚普利和替米沙坦分别增加至8 mg OD和80 mg OD,以使平均动脉压保持在90-115 mmHg之间。两组的调整剂量均保持恒定。首先估计血尿素,血清肌酐和肌酐清除率,然后在第4、12和24周进行估计。结果:培哚普利治疗显示,新诊断和老年高血压患者的血尿素,血清肌酐和肌酐清除率的平均基线值分别为30.88、1.37、64.09和33.68、1.53、55.98。在研究期之后,这些值分别为32.24、1.40、63.97和29.80、1.46、59.23(p值> 0.05)。替米沙坦治疗表明,两组患者的血尿素平均基线值,血清肌酐和肌酐清除率分别为30.88、1.52、59.31和31.72、1.40、65.67。治疗后,两组的这些值分别为31.92、1.43、62.66;和32.20、1.46、61.70(p值> 0.05)。结论:结论是培哚普利和替米沙坦均能显着降低收缩压,舒张压和平均动脉压,而对新诊断和老年高血压患者的肾功能均无明显影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号